Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 5/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 11/20 | 0.44 |
| ▸ | IDO1 | P14902 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30856077 | 0.80 | CYP1A2 (0.51) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL165798 | 0.76 | NOS1 (0.57) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL21873966 | 0.76 | NOS1 (0.61) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL1250107 | 0.76 | NOS1 (0.57) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL27216864 | 0.76 | NOS1 (0.49) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL21271908 | 0.76 | MAPT (0.42) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL30641196 | 0.76 | MAPT (0.42) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL21271929 | 0.73 | NOS1 (0.61) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL2702741 | 0.72 | PIM3 (0.63) | PIM3NOS1PIM1TDO2IDO1 | |
| SCHEMBL2215478 | 0.71 | TDO2 (0.46) | PIM3NOS1PIM1TDO2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098515-A1 | HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | PIM3 164/4885NOS1 3945/4885PIM1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.